Tag: AHA 2024
AHA 2024: Five-year Amulet IDE data show similar outcomes with Amplatzer and Watchman devices
Latest data from the Amulet investigational device exemption (IDE) trial, comparing the Amplatze...
AHA 2024: OPTION trial reports positive outcomes for Watchman FLX at three years after AF ablation
Three-year results from the OPTION clinical trial, comparing the Watchman FLX (Boston Scientific...
AHA 2024: Edoxaban an “effective alternative” to warfarin following valve replacement surgery
Edoxaban may be an effective alternative to warfarin—the current standard of care—for patients under...
AHA 2024: Spironolactone misses primary endpoints in CLEAR SYNERGY trial
Routine use of the blood pressure medication spironolactone among patients who have undergone pe...
